Mana.bio’s Post

YPOG advised lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund, and HTGF | High-Tech Gründerfonds also participated in the investment.   The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.   Congratulations to our client Vesalius and all parties involved!   The YPOG team was led by Martin Schaper and included Dr. Lutz Schreiber, Benjamin Müller, Matthias Treude as well as Cyra Dittberner.   ➡ Link to the press release in the comments below.   #YPOG #PartnersOfGamechangers #VentureCapital #Growth #Funds #Transactions

Great to see the venture build/company creation model gaining more support ( and investment). Many congratulations to General Inception. The concept makes such good business sense, especially in the current investment environment with large investments in later stage opportunities being the trend. This leaves the earlier stages of innovation, (where the future late-stage opportunities originate) needing capitally efficient and creative approaches. We at Cumulus Oncology totally embrace and embody this approach. Great to see visionary investors getting behind this too. The blend of extensive early stage opportunities in Europe coupled with capital and highly experienced mission-focussed teams with successful track records behind them is a winning strategy.

Late-stage fundraising in life sciences remains extremely challenging. So, how do you raise a €100 mio Series C as a European biotech in current markets? How do you convince a new investor to invest for the first time in your Series C round? Thank you Tim Knotnerus, CEO of Agomab Therapeutics , and Felice Verduyn - van Weegen, Partner at EQT Life Sciences, for addressing these and many other questions about Agomab’s recent Series C financing round during LifeScience ORG’s Mastermind: * Fund when you can and not only when you have to; * Focus on your most relevant investors; * Continuously invest and build your most important investor relationships, even if they are not (yet) ready to invest; * Kick off your U.S. investor strategy as early as possible; * As the CEO, consider the unconventional and then lead with conviction. Masterminds are informal peer-to-peer CEO conversations where our members share and discuss relevant transaction and other experiences. Join the conversation at www.lifescienceorg.com Oliver Uecke, Miquel Vila-Perello, Oscar Izeboud, Kristof Vercruysse, Kristoffer Famm, Tom Weaver, Juliane Bernholz, Marc Gitzinger, Camilla Easter, Robert Habib, Katrien Reynders, Clive Dix.HonFBPhS, Dr. Rüdiger Jankowsky, Hanne Callewaert, Simon Skjøde Jensen, Andrew Bruce, Neil Torbett, Prof Dr Arndt Rolfs, Ola (Aleksandra) Wlodek, Maximilien Levesque, Alexandre Reeber, Nawal Ouzren, #biotechnology #lifescience #ceo #fundraising

Learn more about the rapidly maturing #lifescience sector in Calgary at this panel discussion ⬇

💶 🚨 SciRhom has secured a EUR 63 Million Series A financing to accelerate iRhom2-targeting therapies in autoimmune diseases. ⬇ The financing enables us to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy toward clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments. SciRhom aims to push the boundaries in autoimmune medicine by addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signaling pathways, via iRhom2. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including HTGF | High-Tech Gründerfonds and the US-based PhiFund Ventures. We are excited to have attracted such a high-caliber international consortium of investors and appreciate our existing shareholders backing SciRhom in this crucial period of its development. In conjunction with this investment, we are excited to welcome Olivier Litzka, Peter Neubeck, Georgina Askeland, PhD, Dr. Fei Tian, and Varun Gupta to SciRhom’s Board of Directors and look forward to collaborating with them. Stay tuned and follow us here on LinkedIn to learn more about our novel approach as we progress toward initiation of a first clinical study in H2 2024. #venturecapital #financing #funding #fundingalert #SeriesA #iRhom2 #ADAM17 #TACE #autoimmune #IBD #RA #drugdiscovery #antibodyresearch #munichbiotech

Dec 2018 – Dec 2023. 5 years ago, my journey in Gain Therapeutics officially started. I am proud to be associated with Gain, as we moved together as a team from a handful of highly knowledgeable scientists and admins to a NASDAQ listed company and now to a clinical stage one. I would like here to thank (the list would be very long) all the current and past colleagues for their dedication and passion, the current and past external academic collaborators for their science, the patient and research organizations for their wisdom and collaboration. The US+EU+Swiss+Ticino ecosystem and grant organizations for their support, the initial and current investors for believing in us and last but not least Gain’s current and past board members who strategically have and are supporting Gain. Finally, I would like to express my gratitude to the first CEO (Lorenzo Leoni) and Gain’s chairman (Khalid Islam) for having offered me the position. I also would like to thanks Eric Richman for having transitioned us as CEO to the NASDAQ and Matthias Alder for having coordinated as CEO the transition to the clinic. And thanks to Alessandro Bossi for the initial contact to this project (now a solid reality). #ganx #gaintherapeutics #usa #eu #switzerland #ticino #ecosystem #nasdaq #parkinsonsdisease #rarediseases #drugdevelopment #researchcollaboration #science #finance #clinicalresearch #stars #allostery

Well done everyone involved! Qureight is a great investment and looking forward to seeing their growth! Echoing Joe - more announcements coming soon from Guinness Ventures so watch this space! 👀 #venturecapital #eis #vct #healthtech #investment #fundraising

As we move into a month of festitivies 🎄, let's take a look at November's funding highlights in this month's #FUNDLAB. 💸Cytovale raised $84M in Series C 💸Liquid Biopsy company UniversalDx raised $70M in Series B, with Quest Diagnostics as a key investor 💸Nature's Toolbox, Inc. (NTx) announced $47.5M in Series B, led by RA Capital Management 💸Imagine Pharma closed $32.5M in Series A 💸Kythera Labs raised $20M in Series A to fuel expansion of their data technology platform 💸Alternative food ingedient innovator Solar Foods announced €8M in Series B 💸Femasys Inc. securd $6.85M in strategic investment from PharmaCyte Biotech 💸Cromatic announced a funding round of $5.3M What have we missed? Comment your own highlights below ☟ Gilbert Meher

🎂 In 2023, we celebrated 5 years of #StartLab!   👋 When it first opened in March 2018, it could only accommodate 15 companies (HAYA Therapeutics, Gnubiotics Sciences and Volumina Medical were among the first residents).   Today, StartLab can host up to 25 companies in a 1000 m² space. A lot has changed in five years!   What hasn't changed, however, is that StartLab was — and still is — an ideal launchpad for small projects, new start-ups and intensive bootstrap periods.    👇 Discover key figures from the StartLab #community in this handy infographic taken from the Biopôle Review 2023!